Table 4.
Summary of studies on cytoreductive surgery of recurrent endometrial cancer
| Case | PFI (m) | Surgery patients | OS (m) | Optimal definition (cm) | Optimal cytoreduction (%) | Optimal median OS (m) | Suboptimal median OS (m) | |
|---|---|---|---|---|---|---|---|---|
| Scarabelli [7] |
20 |
16.9 |
20 |
NA |
No gross |
65 (13/20) |
12 |
Undefined |
| Campagnutta [8] |
75 |
13 |
75 |
19 |
<=1 |
74.7 (56/75) |
53 |
9 |
| Bristow [9] |
61 |
18.5 |
35 |
28 |
No grossly visible |
65.7 (23/35) |
39 |
13.5 |
| / |
26 |
13 |
/ |
/ |
/ |
/ |
||
| Awtrey [10] |
27 |
20 |
27 |
35 |
<=2 |
67 (18/27) |
43 |
10 |
| This study | 75 | 18 | 75 | 18 | <=1 | 77.3(58/75) | 72 | 22 |
Note. NA, not assessable. PFI, progression free interval. OS, overall survival.